Crossmark

Angiotensin receptor-neprilysin inhibitors improve the outcome of lung cancer patients with hypertension undergoing immune checkpoint inhibitors treatment

Crossref DOI link: https://doi.org/10.1186/s12872-025-05466-1

Published Online: 2025-12-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shang, Conghui

Wang, Hao

Chen, Jindong

Cao, Shuhui

Sun, Yingjia

Sheng, Ziyi

Chu, Tianqing

Zhao, Liang
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (No. 81970276)
License Information

Text and Data Mining valid from 2025-12-27

Version of Record valid from 2026-01-06
More Information

Article History

Received: 8 October 2025

Accepted: 17 December 2025

First Online: 27 December 2025

Declarations

:

: not applicable.

: not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below